Checked
Lunai Bioworks Inc.
Nasdaq: LNAI · Pharmaceutical Preparations · Suite 906 Los Angeles, CA
- Revenue
- $51.99K
- Year ended Jun 30, 2026
- Net income
- -$3.56M
- -6852.0% net margin
- Total assets
- $9.94M
- Diluted EPS
- -$1.06
Company details
As reported to the SEC
- SEC CIK
- 1527728
- Stock
- Nasdaq: LNAI
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- Century City Medical Plaza, 2080 Century City East, Suite 906 Los Angeles, CA 90067
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- June 30
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (453) 917-9840
- Employer ID (EIN)
- 45-2259340
- Last annual report
- 10/13/2026
- Last quarterly report
- 05/15/2026
Formerly: RENOVARO INC. (until 08/26/2025); RENOVARO BIOSCIENCES INC. (until 02/07/2024); Enochian Biosciences Inc (until 08/01/2023); DanDrit Biotech USA, Inc. (until 02/23/2018); Putnam Hills Corp. (until 02/11/2014)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 06/30/2026 | 06/30/2025 | 06/30/2024 | 06/30/2023 | 06/30/2022 |
|---|---|---|---|---|---|
| Revenue | $51.99K | Not reported | Not reported | Not reported | Not reported |
| Operating income | -$8.7M | -$189M | -$81.64M | -$38.56M | -$116.1M |
| Net income | -$3.56M | -$178M | -$88.43M | -$39.68M | -$113.4M |
| Diluted earnings per share | -$1.06 | -$86.27 | -$0.91 | -$0.71 | -$2.16 |
| Research and development | $24.52K | $537.4K | $2.71M | $4.17M | $8.37M |
| Total assets | $9.94M | $8.23M | $163.1M | $58.3M | $84.63M |
| Total liabilities | $18.97M | $29.58M | $31.15M | $11.8M | $12.01M |
| Shareholders' equity | -$9.02M | -$21.35M | $132M | $46.5M | $72.62M |
| Cash and cash equivalents | $1.71M | $92.7K | $220.5K | $1.87M | $9.17M |
| Cash from operations | -$5.29M | -$7.87M | -$10.97M | -$11.77M | -$15.73M |
| Capital expenditures | $1.24K | Not reported | $70.43K | $29.77K | $5.16K |
Subsidiaries
5 companies that Lunai Bioworks Inc. owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| BioSymetrics Inc. | SEC 10-K |
| GEDi Cube Intl Ltd. | SEC 10-K |
| Grace Systems B.V. | SEC 10-K |
| Lunai Bioworks IP, Inc. | SEC 10-K |
| Renovaro Biosciences Denmark ApS | SEC 10-K |
Recent filings
145 recent filings on record
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| S-8 POSSEC filing | 10/23/2026 | None |
| POS AMPost-effective amendment | 10/23/2026 | None |
| S-8 POSSEC filing | 10/23/2026 | None |
| 8-KDelisting or listing rule notice, Director or officer change, Regulation FD disclosure | 10/23/2026 | 10/16/2026 |
| SCHEDULE 13D/AOwnership report (5% holder, active, amended) | 10/15/2026 | None |
| 10-KAnnual report | 10/13/2026 | 06/30/2026 |
| 8-KOther events | 10/09/2026 | 10/09/2026 |
| NT 10-KNotice of late annual report | 09/29/2026 | 06/30/2026 |
| SCHEDULE 13GOwnership report (5% holder, passive) | 07/17/2026 | None |
| 8-KOther events | 06/17/2026 | 06/17/2026 |
| 8-KOther events | 06/16/2026 | 06/11/2026 |
| 8-KOther events | 05/20/2026 | 05/20/2026 |
| 10-QQuarterly report | 05/15/2026 | 03/31/2026 |
| 8-KShareholder vote results | 05/13/2026 | 05/08/2026 |
| 8-K/ADelisting or listing rule notice | 05/11/2026 | 04/27/2026 |
| DEFR14ASEC filing | 05/01/2026 | None |
| 8-KMaterial agreement, Acquisition or sale of assets, Delisting or listing rule notice | 05/01/2026 | 04/27/2026 |
| 8-KOther events | 04/28/2026 | 04/27/2026 |
| DEFA14AAdditional proxy materials | 04/28/2026 | None |
| DEFR14ASEC filing | 04/15/2026 | None |
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Lunai Bioworks Inc.'s CIK number?
- Lunai Bioworks Inc.'s SEC Central Index Key (CIK) is 1527728.
- What is Lunai Bioworks Inc.'s stock ticker?
- Lunai Bioworks Inc. trades as Nasdaq: LNAI.
- What was Lunai Bioworks Inc.'s revenue?
- Lunai Bioworks Inc. reported revenue of $51.99K for the fiscal year ended Jun 30, 2026.
- When does Lunai Bioworks Inc.'s fiscal year end?
- Lunai Bioworks Inc.'s fiscal year end on file with the SEC is June 30; its most recent fiscal year ended Jun 30, 2026.
- Where is Lunai Bioworks Inc. headquartered?
- Lunai Bioworks Inc.'s principal executive office on file with the SEC is in Suite 906 Los Angeles, CA.
- What companies does Lunai Bioworks Inc. own?
- Lunai Bioworks Inc. lists 5 subsidiaries in its SEC filings and other public records, including BioSymetrics Inc., GEDi Cube Intl Ltd., Grace Systems B.V.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026